In this narrative review, we present several pieces of evidence suggesting arginine vasopressin (AVP) neuropeptide receptors as a potential therapeutic target, and copeptin, a surrogate marker of AVP, as an effective biomarker for long-term prognosis and risk stratification in stroke. The gene discussed is AVP; the disease is stroke disorder.